These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. Boczkowski D; Nair SK; Snyder D; Gilboa E J Exp Med; 1996 Aug; 184(2):465-72. PubMed ID: 8760800 [TBL] [Abstract][Full Text] [Related]
5. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
6. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Yang S; Darrow TL; Vervaert CE; Seigler HF Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775 [TBL] [Abstract][Full Text] [Related]
9. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294 [TBL] [Abstract][Full Text] [Related]
10. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491 [TBL] [Abstract][Full Text] [Related]
11. Direct and indirect T cell priming by dendritic cell vaccines. Cayeux S; Richter G; Becker C; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1999 Jan; 29(1):225-34. PubMed ID: 9933104 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780 [TBL] [Abstract][Full Text] [Related]
13. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis]. Pan JP; Weng YS; Wu QQ Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366 [TBL] [Abstract][Full Text] [Related]
14. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
15. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. Paglia P; Chiodoni C; Rodolfo M; Colombo MP J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239 [TBL] [Abstract][Full Text] [Related]
16. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591 [TBL] [Abstract][Full Text] [Related]
18. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730 [TBL] [Abstract][Full Text] [Related]
19. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. Ashley DM; Faiola B; Nair S; Hale LP; Bigner DD; Gilboa E J Exp Med; 1997 Oct; 186(7):1177-82. PubMed ID: 9314567 [TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]